GlaxoSmithKline: Obesity trials
The registry lists 16 Obesity studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 9Phase 2 4Phase 4 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 DiabetesCompletedNCT01725126Phase 2Results posted
- Effect of Orlistat in Body CompositionCompletedNCT00752726Phase 4Results posted
- Feasibility Study of Exenatide by Continuous Subcutaneous InfusionCompletedNCT01857895Phase 1
- Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DMCompletedNCT01648153Phase 2
- A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese SubjectsCompletedNCT01597609Phase 1
- A Study to Characterize Event Related Potential Markers of Attentional Bias Towards Words and Images of FoodTerminatedNCT01366508Phase 1
- Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical TrialsCompletedNCT01332448
- A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.CompletedNCT01195792Phase 2
- Effects of the D3 Antagonist GSK598809 on Food Reward and ReinforcementCompletedNCT01039454Phase 1
- Effects of Repeat Dosing of GSK1521498CompletedNCT00976105Phase 1
- [11C]Carfentanil PET Study of GSK1521498CompletedNCT00976066Phase 1
- A First-Time-In-Human Study in Healthy SubjectsCompletedNCT00857883Phase 1
- Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active DrugsCompletedNCT00494767Phase 1
- An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And InflammationCompletedNCT00388180
- Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 DiabetesCompletedNCT00376038Phase 1
- Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 WeeksCompletedNCT00297180Phase 2